Zai Lab (NASDAQ:ZLAB) CEO Ying Du Sells 7,026 Shares of Stock

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CEO Ying Du sold 7,026 shares of the business’s stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $18.53, for a total value of $130,191.78. Following the sale, the chief executive officer directly owned 1,203,784 shares in the company, valued at $22,306,117.52. This trade represents a 0.58% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Ying Du also recently made the following trade(s):

• On Friday, June 26th, Ying Du sold 24,543 shares of Zai Lab stock. The shares were sold at an average price of $17.46, for a total value of $428,520.78.
• On Thursday, May 14th, Ying Du sold 50,000 shares of Zai Lab stock. The stock was sold at an average price of $20.09, for a total value of $1,004,500.00.
• On Monday, April 6th, Ying Du sold 2,653 shares of Zai Lab stock. The stock was sold at an average price of $20.45, for a total value of $54,253.85.
• On Thursday, April 2nd, Ying Du sold 5,576 shares of Zai Lab stock. The shares were sold at an average price of $20.39, for a total value of $113,694.64.

Zai Lab Stock Up 0.8%

Shares of ZLAB stock opened at $19.15 on Thursday. Zai Lab Limited Unsponsored ADR has a fifty-two week low of $15.96 and a fifty-two week high of $41.20. The stock has a market cap of $2.17 billion, a P/E ratio of -11.82 and a beta of 0.78. The business has a fifty day simple moving average of $19.07 and a 200-day simple moving average of $18.97.

Zai Lab (NASDAQ:ZLAB) last released its quarterly earnings data on Wednesday, April 1st. The company reported ($0.50) EPS for the quarter. The business had revenue of $99.61 million during the quarter. Zai Lab had a negative return on equity of 24.32% and a negative net margin of 39.29%. On average, sell-side analysts anticipate that Zai Lab Limited Unsponsored ADR will post -2.23 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently commented on ZLAB. JPMorgan Chase & Co. lowered their price target on shares of Zai Lab from $39.00 to $32.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 18th. Wall Street Zen lowered Zai Lab from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Weiss Ratings upgraded Zai Lab from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, June 26th. Finally, Citigroup dropped their price target on Zai Lab from $47.00 to $44.00 and set a “buy” rating for the company in a research report on Friday, May 8th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $40.00.

Institutional Investors Weigh In On Zai Lab

An institutional investor recently raised its position in Zai Lab stock. SG Americas Securities LLC lifted its position in shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) by 6.6% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 10,396 shares of the company’s stock after buying an additional 642 shares during the period. SG Americas Securities LLC’s holdings in Zai Lab were worth $183,000 as of its most recent SEC filing. 41.65% of the stock is currently owned by institutional investors and hedge funds.

About Zai Lab

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.